Inhibrx Biosciences Balance Sheet
NASDAQ: INBXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Inhibrx Biosciences financial position
At the end of fiscal 2025, Inhibrx Biosciences reported total assets of $146.5 million, down 19.0% from a year earlier against total liabilities of $138.5 million. Shareholders' equity stood at $8.0 million, or 5.5% of assets. The company held $124.2 million in cash and equivalents against $100.6 million of debt, a net cash position of $23.7 million.
The current ratio (current assets divided by current liabilities) was 3.93, meaning short-term assets cover obligations due within a year. Debt-to-equity was 12.58.
Summary generated from market data by MetaCap's automated system. Methodology
Inhibrx Biosciences balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Cash & Equivalents | 124.22M | 152.60M | 277.92M |
| Total Current Assets | 132.83M | 160.40M | 295.36M |
| Property, Plant & Equipment | 3.73M | 6.20M | 6.42M |
| Total Assets | 146.48M | 180.77M | 307.89M |
| Accounts Payable | 5.94M | 9.24M | 10.95M |
| Total Current Liabilities | 33.80M | 40.73M | 56.31M |
| Long-Term Debt | 100.56M | 0 | 206.97M |
| Total Liabilities | 138.49M | 47.18M | 264.39M |
| Shareholders' Equity | 7.99M | 133.58M | 43.50M |
| Retained Earnings | -246.19M | -106.13M | -613.73M |
| Total Debt | 100.56M | 0 | 206.97M |
| Net Cash (Debt) | 23.66M | 152.60M | 70.96M |
| Shares Outstanding | 14.58M | 14.48M | 47.37M |
This table shows 3 annual periods of Inhibrx Biosciences's balance sheet, from FY 2025 back to FY 2023, across 13 line items including cash & equivalents, total current assets, property, plant & equipment. Values in USD; B = billions, M = millions. Fiscal periods follow INBX's reporting calendar. What is a balance sheet?